Randomized controlled trial in gastric or gastroesophageal junction adenocarcinoma undergoing systemic therapy over two decades.

[1]  Chang-ming Huang,et al.  Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer , 2021, JAMA network open.

[2]  H. Zeh,et al.  The changing face of gastric cancer: epidemiologic trends and advances in novel therapies , 2020, Cancer Gene Therapy.

[3]  C. Fuller,et al.  Professional Medical Writer Assistance in Oncology Clinical Trials , 2020, The oncologist.

[4]  Jianwen Xie,et al.  Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer , 2020, Annals of surgery.

[5]  R. Jagsi,et al.  Association of Industry Sponsorship With Cancer Clinical Trial Accrual. , 2020, JAMA oncology.

[6]  D. Park,et al.  Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). , 2019, Annals of surgery.

[7]  J. Ji,et al.  Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. , 2019, JAMA.

[8]  Prashanth Rawla,et al.  Epidemiology of gastric cancer: global trends, risk factors and prevention , 2018, Przeglad gastroenterologiczny.

[9]  Huixun Jia,et al.  Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  U. Dafni,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Korenstein,et al.  Impact of industry collaboration on randomised controlled trials in oncology. , 2017, European journal of cancer.

[12]  I. Tannock,et al.  Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Adam Jacobs,et al.  Mythbusting Medical Writing: Goodbye, Ghosts! Hello, Help! , 2016, Accountability in research.

[14]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  K. Fock.  Review article: the epidemiology and prevention of gastric cancer , 2014, Alimentary pharmacology & therapeutics.

[16]  L. Saltz.  Progress in cancer care: the hope, the hype, and the gap between reality and perception. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Park,et al.  Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). , 2016, Annals of surgery.